Omentin-1: a newly discovered warrior against metabolic related diseases. (4th March 2022)

• Record Type: Journal Article
• Authors: Zhao, Aizhen; Xiao, Haoxiang; Zhu, Yanli; Liu, Shuai; Zhang, Shaofei; Yang, Zhi; Du, Luyang; Li, Xiyang; Niu, Xiaochen; Wang, Changyu; Yang, Yang; Tian, Ye
• Is Part Of: Expert opinion on therapeutic targets. Volume 26:Number 3(2022)
• Page Start: 275
• Page End: 289
• Publication Date: 2022-03-04
• Subjects: Omentin-1 -- Biological actions -- Cancer -- Type 2 diabetes mellitus -- Atherosclerosis -- Bone metabolic diseases; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2022.2037556
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction: Chronic metabolism-related diseases are challenging clinical problems. Omentin-1 is mainly expressed in stromal vascular cells of adipose tissue and can also be expressed in airway goblet cells, mesothelial cells, and vascular cells. Omentin-1 has been found to exert important anti-inflammatory, antioxidative and anti-apoptotic roles and to regulate endothelial dysfunction. Moreover, omentin-1 also has protective effects against cancer, atherosclerosis, type 2 diabetes mellitus, and bone metabolic diseases. The current review will discuss the therapeutic potential of omentin-1. Areas covered: This review summarizes the biological actions of omentin-1 and provides an overview of omentin-1 in metabolic-related diseases. The relevant literature was derived from a PubMed search spanning 1998–2021 using these search terms: omentin-1, atherosclerosis, diabetes mellitus, bone, cancer, inflammation, and oxidative stress. Expert opinion: As a novel adipocytokine, omentin-1 is a promising therapeutic target in metabolic-related diseases. Preclinical animal studies have shown encouraging results. Moreover, circulating omentin-1 has excellent potential as a noninvasive biomarker. In the future, strategies for regulating omentin-1 need to be investigated further in clinical trials in a large cohort.